Soehnlein, Oliver http://orcid.org/0000-0002-7854-0694
Article History
First Online: 6 February 2023
Competing interests
: O.S. receives support from Novo Nordisk to circadian rhythms in atherosclerosis and to target histones H4 in inflammation; O.S. holds patents on histone neutralization and interference with chemokine heteromers.